$PRVA

Mountcastle David sold $433K of PRVA

Mountcastle David (EVP & Chief Financial Officer) sold 17,196 shares of Privia Health Group, Inc. (PRVA) at $25.18 ($0.43M total) on 2026-06-26 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Mountcastle David
Published Jun 30, 2026, 8:08 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 30, 2026, 8:19 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$PRVA
Neutral
high confidence
Mentioned
$PRVA
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PRVANeutralLow
01

Why it matters

The disclosed open-market sale by the CFO under a 10b5-1 plan is generally treated as routine and not a fundamental change signal by itself.

02

Market read

Traders may note the disclosure for sentiment/positioning, but it is unlikely to drive a major repricing without additional fundamental news.

03

What to watch

The article provides only the sale details; it does not state whether there were concurrent buys, option exercises, or broader insider activity trends.

Relevance 3/10Novelty 3/10Timing: Filed June 30; transaction dated June 26 (insider sale disclosure timing).

Background

The article is an SEC Form 4 insider transaction disclosure for Privia Health Group, Inc.

Company-level read

Ticker impact

$PRVANeutralHigh confidence
Context

Privia Health Group CFO David Mountcastle sold 17,196 shares in an open-market transaction under a 10b5-1 plan, totaling about $433K.

Expected impact

Low likelihood of a sustained price move solely from this Form 4 sale; any impact would be sentiment-driven and short-lived.

Evidence & confidence

The filing is a Form 4 insider sale with explicit 10b5-1 pre-arrangement, which reduces the informational content versus discretionary selling.

Market effects

Minimal—this is company-specific insider activity with no sector-wide catalyst described.

None indicated.

None indicated.

Counterpoint

Even with 10b5-1, repeated insider selling can still coincide with management’s view of valuation or liquidity needs; traders may watch for clustering of sales.

Key entities

  • Privia Health Group, Inc.

    Subject of the Form 4 insider transaction; CFO David Mountcastle sold shares totaling ~$432,995.28.

  • David Mountcastle

    EVP & Chief Financial Officer who executed the open-market sale under a pre-arranged 10b5-1 plan.

Related articles

$PRVAHighAI 9/10

Privia Health Group, Inc. (PRVA): Results of Operations and Financial Condition

Privia Health Group, Inc. (PRVA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex-9912q26earningrelease.htm EX-99.1 Document Exhibit 99.1 Privia Health Reports Strong Second Quarter and Year-to-Date 2026 Results – 2Q’26 Net Income of $9.0M, +236.7% from 2Q’25 – 2Q’26 Adjusted EBITDA of $37.4M, +29.1% from 2Q’25 – Full-Year 2026 Guidance Raised for